Background: There is little information comparing the costs of
specific surgical procedures performed in Canada and those done in the United
States. The objective of this study was to compare the in-hospital costs
associated with primary total hip arthroplasty performed in the two
countries.
Methods: In-hospital costs of 1679 consecutive patients (940
Canadian and 739 American patients) who underwent total hip arthroplasty were
extracted from three Canadian and three United States teaching hospitals
between 1997 and 2001. Participating hospitals used the same cost accounting
system to provide per-patient demographic, clinical, and cost data. Canadian
dollar costs were converted to United States dollar costs with use of
purchasing power parities.
Results: The baseline clinical characteristics of patients
undergoing total hip arthroplasty in Canada and the United States were
similar. The American patients were a mean of 4.6 years older than the
Canadian patients (mean [and standard deviation], 67.8 ± 12.4 years
compared with 63.2 ± 14.9 years). The median cost for the primary
arthroplasty was $6080 (mean [and standard error of the mean], $6766 ±
$119) at the three Canadian hospitals and $12,846 (mean, $13,339 ±
$131) at the United States hospitals (p < 0.0001). The mean length of stay
(and standard deviation) was 7.2 ± 4.7 days for the Canadian patients
and 4.2 ± 2.0 days for the American patients. Implants at one hospital
in the United States were found to be four times more costly than those in a
Canadian hospital.
Conclusions: Higher in-hospital costs were found for the American
hospitals despite the fact that they had a significantly shorter patient
length of stay compared with Canadian centers (p < 0.0001). Canadian
hospitals should follow the lead of their counterparts in the United States
and implement strategies to decrease the length of stay in the hospital, while
institutions in the United States should revisit their ability to better
manage the costs related to a primary total hip arthroplasty, particularly by
controlling unit costs.
Level of Evidence: Economic and decision analysis, Level
II-1 (clinically sensible costs and alternatives; values obtained from
limited studies; multiway sensitivity analyses). See Instructions to Authors
for a complete description of levels of evidence.